Allosteric Antagonism of Calcium Channels With Small Molecules for Relief of Neuropathic Pain

Technology #ua16-145

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Rajesh Khanna
Associate Professor, Pharmacology
Vijay Gokhale
Senior Research Scientist, BIO5
Managed By
Lisa Lin
Licensing Manager (520) 626-6969

Title: Small-Molecules for the Potential Treatment of Pain

 

Invention: The proposed small molecules can act via a novel mechanism, that mechanism being allosteric antagonism of calcium channels, to be antinociceptive against acute, inflammatory and chronic neuropathic pain.

 

Background: More than 1.5 billion people worldwide suffer from chronic pain and approximately 3-4.5% of the global population suffers from neuropathic pain, with incidence rate increasing complementary to age. Opioids remain the gold standard for the treatment of pain but are limited by poor side effect profiles such as emesis, constipation, dependence/addiction and respiratory depression. Despite a myriad of analgesic compounds on the market, nearly two thirds of chronic pain patients report inadequate pain relief. Therefore, a new approach in the development of pain management is necessary.

Applications:

  • Treatment of chronic and neuropathic pain
  • Treatment of other neuropathologic diseases (ex. Alzheimer’s disease and schizophrenia)

 

Advantages:

  • Potential to overcome the side effects of Ziconotide, the current FDA-approved therapy for chronic pain including nausea/vomiting, somnolence, vertigo, muscle spasms, myalgia, insomnia, anxiety, tremor, memory impairment and induced psychiatric disorders, and addiction
  • Potential to overcome the difficult dosing regimens and narrow therapeutic window of Ziconotide
  • Novel small-molecules, although biological studies are required to demonstrate their analgesic activity

 

Licensing Manager: 

Lisa Lin

lisal@tla.arizona.edu

(520) 626-6969